Literature DB >> 27197907

Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.

Matthew S Shotwell1, Ross Nesbitt2, Phillip N Madonia2, Edward R Gould2, Michael J Connor3, Charbel Salem4, Olufemi A Aduroja5, Milen Amde6, Joseph J Groszek2, Peilin Wei1, Maria E Taylor7, Ashita J Tolwani7, William H Fissell8.   

Abstract

BACKGROUND AND OBJECTIVES: Infection is the most common cause of death in severe AKI, but many patients receiving continuous RRT do not reach target antibiotic concentrations in plasma. Extended infusion of β-lactams is associated with improved target attainment in critically ill patients; thus, we hypothesized that extended infusion piperacillin-tazobactam would improve piperacillin target attainment compared with short infusion in patients receiving continuous RRT. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted an institutional review board-approved observational cohort study of piperacillin-tazobactam pharmacokinetics and pharmacodynamics in critically ill patients receiving continuous venovenous hemodialysis and hemodiafiltration at three tertiary care hospitals between 2007 and 2015. Antibiotic concentrations in blood and/or dialysate samples were measured by liquid chromatography, and one- and two-compartment pharmacokinetic models were fitted to the data using nonlinear mixed effects regression. Target attainment for piperacillin was defined as achieving four times the minimum inhibitory concentration of 16 μg/ml for >50% of the dosing cycle. The probabilities of target attainment for a range of doses, frequencies, and infusion durations were estimated using a Monte Carlo simulation method. Target attainment was also examined as a function of patient weight and continuous RRT effluent rate.
RESULTS: Sixty-eight participants had data for analysis. Regardless of infusion duration, 6 g/d piperacillin was associated with ≤45% target attainment, whereas 12 g/d was associated with ≥95% target attainment. For 8 and 9 g/d, target attainment ranged between 68% and 85%. The probability of target attainment was lower at higher effluent rates and patient weights. For all doses, frequencies, patient weights, and continuous RRT effluent rates, extended infusion was associated with higher probability of target attainment compared with short infusion.
CONCLUSIONS: Extended infusions of piperacillin-tazobactam are associated with greater probability of target attainment in patients receiving continuous RRT.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  Acute Kidney Injury; Anti-Bacterial Agents; Critical Illness; Dialysis Solutions; Humans; Microbial Sensitivity Tests; Renal Replacement Therapy; extended-infusion; pharmacokinetics; piperacillin

Mesh:

Substances:

Year:  2016        PMID: 27197907      PMCID: PMC4974884          DOI: 10.2215/CJN.10260915

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  24 in total

1.  Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.

Authors:  Seth R Bauer; Charbel Salem; Michael J Connor; Joseph Groszek; Maria E Taylor; Peilin Wei; Ashita J Tolwani; William H Fissell
Journal:  Clin J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 8.237

2.  Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

Authors:  Brian VanScoy; Rodrigo E Mendes; Anthony M Nicasio; Mariana Castanheira; Catharine C Bulik; Olanrewaju O Okusanya; Sujata M Bhavnani; Alan Forrest; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

3.  Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.

Authors:  Glenn M Chertow; Elisabeth Burdick; Melissa Honour; Joseph V Bonventre; David W Bates
Journal:  J Am Soc Nephrol       Date:  2005-09-21       Impact factor: 10.121

4.  Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  Gary R Matzke; George R Aronoff; Arthur J Atkinson; William M Bennett; Brian S Decker; Kai-Uwe Eckardt; Thomas Golper; Darren W Grabe; Bertram Kasiske; Frieder Keller; Jan T Kielstein; Ravindra Mehta; Bruce A Mueller; Deborah A Pasko; Franz Schaefer; Domenic A Sica; Lesley A Inker; Jason G Umans; Patrick Murray
Journal:  Kidney Int       Date:  2011-09-14       Impact factor: 10.612

5.  Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis.

Authors:  Michael J Connor; Charbel Salem; Seth R Bauer; Christina L Hofmann; Joseph Groszek; Robert Butler; Susan J Rehm; William H Fissell
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

6.  Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.

Authors:  Janattul-Ain Jamal; Darren M Roberts; Andrew A Udy; Mohd-Basri Mat-Nor; Fariz-Safhan Mohamad-Nor; Steven C Wallis; Jeffrey Lipman; Jason A Roberts
Journal:  Int J Antimicrob Agents       Date:  2015-03-28       Impact factor: 5.283

7.  Temporal changes in incidence of dialysis-requiring AKI.

Authors:  Raymond K Hsu; Charles E McCulloch; R Adams Dudley; Lowell J Lo; Chi-yuan Hsu
Journal:  J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 10.121

8.  Intensity of renal support in critically ill patients with acute kidney injury.

Authors:  Paul M Palevsky; Jane Hongyuan Zhang; Theresa Z O'Connor; Glenn M Chertow; Susan T Crowley; Devasmita Choudhury; Kevin Finkel; John A Kellum; Emil Paganini; Roland M H Schein; Mark W Smith; Kathleen M Swanson; B Taylor Thompson; Anitha Vijayan; Suzanne Watnick; Robert A Star; Peter Peduzzi
Journal:  N Engl J Med       Date:  2008-05-20       Impact factor: 91.245

9.  Pharmacokinetics and pharmacodynamics of imipenem and meropenem in critically ill patients treated with continuous venovenous hemodialysis.

Authors:  David Afshartous; Seth R Bauer; Michael J Connor; Olufemi A Aduroja; Milen Amde; Charbel Salem; Joseph J Groszek; William H Fissell
Journal:  Am J Kidney Dis       Date:  2013-10-19       Impact factor: 8.860

10.  Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis.

Authors:  Jose Garnacho-Montero; Teresa Aldabo-Pallas; Carmen Garnacho-Montero; Aurelio Cayuela; Rocio Jiménez; Sonia Barroso; Carlos Ortiz-Leyba
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more
  6 in total

1.  What's new in pharmacokinetics of antimicrobials in AKI and RRT?

Authors:  Jason A Roberts; Jean-Yves Lefrant; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2017-04-06       Impact factor: 17.440

Review 2.  Extracorporeal organ support (ECOS) in critical illness and acute kidney injury: from native to artificial organ crosstalk.

Authors:  Faeq Husain-Syed; Zaccaria Ricci; Daniel Brodie; Jean-Louis Vincent; V Marco Ranieri; Arthur S Slutsky; Fabio Silvio Taccone; Luciano Gattinoni; Claudio Ronco
Journal:  Intensive Care Med       Date:  2018-07-24       Impact factor: 17.440

Review 3.  Piperacillin-tazobactam as alternative to carbapenems for ICU patients.

Authors:  Benoit Pilmis; Vincent Jullien; Alexis Tabah; Jean-Ralph Zahar; Christian Brun-Buisson
Journal:  Ann Intensive Care       Date:  2017-11-10       Impact factor: 6.925

Review 4.  Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years.

Authors:  Ling-Ling Zhu; Quan Zhou
Journal:  Infect Drug Resist       Date:  2018-08-08       Impact factor: 4.003

Review 5.  Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.

Authors:  Daniel J Selig; Jesse P DeLuca; Kevin K Chung; Kaitlin A Pruskowski; Jeffrey R Livezey; Robert J Nadeau; Elaine D Por; Kevin S Akers
Journal:  J Clin Pharm Ther       Date:  2022-03-29       Impact factor: 2.145

Review 6.  Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.

Authors:  Lu Li; Xin Li; Yanzhe Xia; Yanqi Chu; Haili Zhong; Jia Li; Pei Liang; Yishan Bu; Rui Zhao; Yun Liao; Ping Yang; Xiaoyang Lu; Saiping Jiang
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.